Interferon beta-1b for COVID-19
Open Access
- 8 May 2020
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 395 (10238), 1670-1671
- https://doi.org/10.1016/s0140-6736(20)31101-6
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Evaluation of antiviral therapies for coronavirus disease 2019 pneumonia in Shanghai, ChinaJournal of Medical Virology, 2020
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trialThe Lancet, 2020
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19New England Journal of Medicine, 2020
- Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019Clinical Infectious Diseases, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational StudyClinical Infectious Diseases, 2019
- ProTox-II: a webserver for the prediction of toxicity of chemicalsNucleic Acids Research, 2018
- Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort studyThe Lancet Infectious Diseases, 2014
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004
- Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR ChinaJournal of Medical Microbiology, 2003